Food and Drug Administration (FDA)-approved glucagon-like peptide-1 receptor agonists (GLP-1) anti-obesity medications, such as Zepbound and Wegovy , are flying off pharmacy shelves
TDN, in particular, may represent a complementary anti-obesity or anti-diabetes agent with the benefits of weight and glucose control, but without the gastrointestinal side effects that often limit GLP-1 therapies
In diabetics and patients with renal insufficiency, the excretion of carnitine is increased
Often, the prescription is rest, however, there are certain steps he or she should take to start, accelerate, and improve the recovery process
Pallotta V, Gevi F, DAlessandro A, Zolla L